KROS Stock Cash Flow Statements

Keros Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Keros Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31

cash flows from operating activities:
net income	-30,696,000	148,451,000	-46,026,000	-52,956,000	-45,257,000	-43,114,000	-40,243,000	-39,440,000	-37,505,000	-35,804,000	-29,718,000	-23,509,000	-27,266,000	-24,186,000	-6,940,000	-20,297,000	-15,622,000	-15,885,000	-10,676,000	-12,036,000	-10,757,000	-11,892,000
adjustments to reconcile net income to net cash from operating activities:
depreciation expense	370,000	344,000	332,000	314,000	306,000	277,000	247,000	210,000	191,000	167,000	127,000	126,000	308,000	113,000	104,000	103,000	91,000	80,000	75,000	72,000	68,000	63,000
gain on disposal of fixed asset
stock-based compensation expense	8,542,000	8,863,000	9,200,000	8,817,000	8,785,000	8,070,000	7,324,000	8,711,000	7,041,000	5,687,000	4,746,000	4,754,000	4,794,000	4,388,000	3,295,000	3,084,000	2,849,000	2,494,000	1,522,000	1,424,000	1,139,000	12,000
non-cash lease expense	595,000	584,000	572,000	563,000	346,000	339,000	335,000	341,000	354,000	522,000	321,000	211,000	206,000	203,000	198,000	120,000	103,000	99,000	98,000	49,000	91,000	89,000
changes in operating assets and liabilities:
accounts receivable	1,475,000	-14,549,000	-2,354,000	-384,000	222,000	-83,000					0	0	0	18,000,000
prepaid expenses and other current assets	-5,100,000	4,543,000	-5,246,000	5,873,000	-6,366,000	-4,478,000	539,000	-4,260,000	-1,489,000	-4,074,000	-270,000	287,000	-4,102,000	764,000	1,327,000	-521,000	-3,425,000	1,071,000	756,000	1,224,000	-2,633,000	-816,000
other assets	463,000	1,593,000	-469,000	491,000							0
accounts payable	-1,368,000	2,019,000	-293,000	-1,592,000	1,613,000	23,000	1,044,000	-182,000	-570,000	1,322,000	595,000	-4,994,000	4,659,000	-668,000	823,000	1,439,000	-1,636,000	859,000	433,000	-3,136,000	2,957,000	-193,000
right-of-use assets and operating lease liabilities	-459,000	-448,000
deferred revenue	-2,383,000	3,308,000
current tax liability	-3,722,000	10,043,000
accrued expenses and other current liabilities	2,674,000	-3,580,000	-1,299,000	8,705,000	900,000	-5,354,000	5,787,000	274,000	1,173,000	-1,977,000	4,263,000	1,281,000	-583,000	361,000	-97,000	1,651,000	204,000	894,000	-85,000	1,655,000	-2,251,000	3,271,000
net cash from operating activities	-29,623,000	161,171,000	-46,008,000	-30,500,000	-39,801,000	-44,560,000	-25,459,000	-33,982,000	-30,832,000	-34,235,000	-21,443,000	-24,602,000	-22,590,000	-1,427,000	-19,565,000	-14,441,000	-17,637,000	-10,505,000	-7,991,000	-10,856,000	-9,927,000	-8,120,000
capex	-720,000	-565,000	-289,000	-386,000	-310,000	-946,000	-541,000	-550,000	-311,000	-1,062,000	-351,000	-176,000	-567,000	-147,000	-159,000	-145,000	-510,000	-210,000	-60,000	-30,000	-28,000	-176,000
free cash flows	-30,343,000	160,606,000	-46,297,000	-30,886,000	-40,111,000	-45,506,000	-26,000,000	-34,532,000	-31,143,000	-35,297,000	-21,794,000	-24,778,000	-23,157,000	-1,574,000	-19,724,000	-14,586,000	-18,147,000	-10,715,000	-8,051,000	-10,886,000	-9,955,000	-8,296,000
cash flows from investing activities:
purchase of property and equipment	-720,000	-565,000	-289,000	-386,000	-310,000	-946,000	-541,000	-550,000	-311,000	-1,062,000	-351,000	-176,000	-567,000	-147,000	-159,000	-145,000	-510,000	-210,000	-60,000	-30,000	-28,000	-176,000
net cash from investing activities	-720,000	-565,000	-289,000	-386,000	-310,000	-946,000	-541,000	-550,000	-311,000	-1,062,000	-351,000	-176,000	-567,000	-147,000	-159,000	-145,000	-510,000	-210,000	-60,000	-30,000	-28,000	-176,000
cash flows from financing activities:
proceeds from issuance of common stock, net of underwriting discounts			0	0	0	151,340,000
payment of issuance costs			0	0	-24,000	-259,000	-67,000															-219,000
proceeds from issuance of common stock under the atm agreement, net of commissions			73,099,000	155,066,000
payment of issuance costs associated with issuance of common stock under the atm agreement			0	-130,000
proceeds from exercise of stock options	17,000	4,000	2,445,000	1,008,000	2,967,000	5,721,000	804,000	311,000	1,740,000	370,000	102,000	96,000	502,000	118,000	245,000	35,000	57,000	42,000	7,000	9,000	9,000	13,000
net cash from financing activities	17,000	4,000	75,544,000	155,944,000	3,531,000	156,802,000	69,254,000	284,000	1,740,000	107,678,000	61,416,000	48,583,000	10,192,000	118,000	28,416,000	35,000	57,000	42,000	140,117,000	9,000	100,124,000	55,794,000
net increase in cash, cash equivalents and restricted cash	-30,326,000	160,610,000	29,247,000	125,058,000	-36,580,000	111,296,000	43,254,000	-34,248,000	-29,403,000	72,381,000	39,622,000				8,692,000	-14,551,000	-18,090,000	-10,673,000	132,066,000	-10,877,000
cash, cash equivalents and restricted cash at beginning of period	0	561,380,000		0	0	332,359,000		0	0	280,375,000		0	0	231,369,000		0	0	265,991,000		0	0	7,135,000
cash, cash equivalents and restricted cash at end of period	-30,326,000	721,990,000		125,058,000	-36,580,000	443,655,000		-34,248,000	-29,403,000	352,756,000		23,805,000	-12,965,000	229,913,000		-14,551,000	-18,090,000	255,318,000		-10,877,000	90,169,000	54,633,000
supplemental disclosure of cash flow information:
cash paid for federal income taxes
property and equipment purchases in accounts payable and accrued expenses	-1,000	15,000		2,000	-146,000	230,000
issuance costs associated with the atm agreement in accounts payable and accrued expenses
loss on disposal of fixed asset							0	0	0	4,000	1,000				26,000	0
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
property and equipment purchases in accounts payable								5,000	34,000	21,000		-11,000	-63,000	87,000
issuance costs in accrued and accounts payable
right-of-use assets obtained in exchange for operating lease obligation			0				0	0	0	1,338,000
right-to-use assets and operating lease liabilities				-331,000	-324,000	-240,000		364,000	-27,000	-82,000
other liabilities															-16,000	-16,000	-15,000	-15,000	-15,000	-14,000	-13,000	-15,000
proceeds from issuance of common stock, net of offering cost							68,517,000	0	0	107,308,000	61,401,000	48,487,000
property and equipment purchases still in accounts payable															-124,000
issuance cost still in accrued and accounts payable
issuance cost in accrued expenses												11,000
change in right-to-use asset
operating lease liabilities													-606,000	-402,000		605,000	-106,000	-102,000	-99,000	-94,000	-93,000	-90,000
net decrease in cash, cash equivalents and restricted cash													-12,965,000	-1,456,000
changes in fair value of preferred stock tranche obligation																			0	0	0	1,490,000
research and development incentive receivable																			0	0	805,000	117,000
deferred ipo costs																			0	0	760,000	-156,000
proceeds from issuance of series c preferred stock																			0	0	0	56,000,000
payment of series c preferred stock issuance costs																			0	0
proceeds from issuance of common stock, from the initial public offering, net of underwriting discounts of 7,728
payment of initial public offering costs																			0	0
proceeds from issuance of common stock, from follow-on financing, net of underwriting discounts of 8,970
payment of follow-on financing offering costs
settlement of preferred stock tranche obligation																			0	0	0	6,446,000
conversion of preferred stock into common stock upon closing of initial public offering																			0	0
change in right to use asset
proceeds from issuance of common stock, from the initial public offering, net of offering costs of 7,728
deferred ipo costs in accounts payable and accrued expenses																						1,259,000
cash paid for taxes
proceeds from issuance of common stock from the initial public offering, net of underwriting discounts of 7,728																				0
net increase/(decrease) in cash, cash equivalents and restricted cash																						47,498,000

We provide you with 20 years of cash flow statements for Keros Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Keros Therapeutics stock. Explore the full financial landscape of Keros Therapeutics stock with our expertly curated income statements.

The information provided in this report about Keros Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.